Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs), today announced that it has appointed Laszlo Radvanyi, PhD, as its chief scientific officer (CSO).

A renowned expert in tumor immunology and adaptive T-cell therapy, Dr. Radvanyi will be responsible for developing novel technologies to produce next-generation TILs with higher therapeutic potency and reduced manufacturing costs. These technologies will be based on two different platforms: one will use clinically sorted TILs to enhance tumor response, and the other will utilize genetically modified T-cells to modulate expression of specific checkpoint receptors on the cell surface.

As CSO, Dr. Radvanyi will also research additional tumor indications for TILs, including lung, cervical and breast cancer, as the company continues to advance its clinical programs in metastatic melanoma.

"Laszlo's expertise in adaptive T-cell therapy will be critical to our efforts to expand clinical applications for TIL therapy, while continuing to refine and enhance the underlying technology," said Manish Singh, PhD, Lion's chairman and chief executive officer. "For the past decade, Laszlo has conducted extensive research on TILs not only in the clinical setting, but also in relation to various other factors that affect tumor immune response. We are therefore thrilled to welcome him to our leadership team as we continue to investigate the potential of TIL therapy to treat, and potentially cure, a wide variety of solid tumors."

Dr. Radvanyi has been conducting clinical research on TILs for ten years, and has more than 25 years of experience studying cellular and molecular immunology. Prior to joining Lion Biotechnologies, he served as professor of melanoma and breast medical oncology at MD Anderson Cancer Center in Houston, TX since 2005. There, he conducted clinical studies on TIL therapy in metastatic melanoma, in addition to performing basic and translational research to identify relevant T-cell therapy biomarkers, enhance the anti-tumor function of expanded T-cells, and improve manufacturing methods for eventual commercialization of T-cell therapy.

Previously, Dr. Radvanyi served as senior scientist in the immunology group at Sanofi-Pasteur in Toronto, where he focused on antigen discovery and developing breast cancer vaccines. He has consulted on immunotherapy development for a number of pharmaceutical companies, and currently serves on the scientific advisory board of Aethlon Medical, Inc. Dr. Radvanyi has authored more than 87 manuscripts, is a reviewer for several journals in the tumor immunology and immunotherapy space, and has sat on many national and international grant review panels. He holds a PhD in clinical biochemistry from the University of Toronto, and completed a post-doctoral fellowship at Harvard Medical School.

About Lion Biotechnologies

Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.

CONTACT: Investor Relations
         The Trout Group
         Gitanjali Jain Ogawa
         646-378-2949
         gogawa@troutgroup.com